Anixa biosciences stock.
When Anixa Biosciences last reported its balance sheet in January 2023, it had zero debt and cash worth US$28m. Importantly, its cash burn was US$7.3m over the trailing twelve months. So it had a ...
Anixa Biosciences Inc’s trailing 12-month revenue is $0.2 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.320 per share for the current fiscal year. Anixa Biosciences Inc does not currently pay a dividend.When Anixa Biosciences last reported its balance sheet in January 2023, it had zero debt and cash worth US$28m. Importantly, its cash burn was US$7.3m over the trailing twelve months. So it had a ...Anixa Biosciences Inc Follow Share $3.31 After Hours: $3.54 (6.83%) +0.23 Closed: Nov 29, 4:02:36 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Ardelyx Inc $4.37 ARDX6.85% Armata... Currently, the analyst consensus on Anixa Biosciences is a Moderate Buy with an average price target of $12.00. See today’s best-performing stocks on TipRanks >> ANIX market cap is currently ...Jun 22, 2023 · ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share. Anixa Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 3rd, 2024 based off prior year's report dates. Read More.
Anixa Biosciences, Inc. Analyst Report: Moderna, Inc. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA ...
Dec 1, 2023 · Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share. Anixa Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 3rd, 2024 based off prior year's report dates. Read More. Get Anixa Biosciences Inc (ANIX.PH) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsAccording to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $10.83 with a high of $12.00 and a low of $9.00.Oct 23, 2023. Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardPhone Number 6315495974. Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer ...
Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and ...
Dec 1, 2023 · See the latest Anixa Biosciences Inc stock price (ANIX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine. The data presented showed that in the …Anixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA Securities8 hari yang lalu ... SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company ...Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt ...According to 1 Wall Street analyst that have issued a 1 year ANIX price target, the average ANIX price target is $12.00, with the highest ANIX stock price ...
Complete Anixa Biosciences Inc. stock information by Barron's. View real-time ANIX stock price and news, along with industry-best analysis.Anixa Biosciences, Inc. Common Stock (ANIX) Stock Price, Quote, News & History | Nasdaq Created with Sketch. Market Activity Funds + ETFs P/E & PEG Ratios when …Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual ...According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $11.0 with a high of $12.00 and a low of $9.00.Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Anixa is focused on the treatment and prevention of cancer. Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology. Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...
Anixa Biosciences plunges on upsizing stock offering to $22.5M SA News Tue, Mar. 23, 2021 2 Comments. Anixa Biosciences to raise $10M in bought deal offering SA News Mon, Mar. 22, 2021 1 Comment.SAN JOSE, Calif., Aug. 15, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases ...
Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial. SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National …Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...About ANIX Stock Exchange Ticker Symbol Financial Performance Financial Statements Analyst Forecast According to 2 analysts, the average rating for ANIX stock …Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Nov 22, 2023 · Get Anixa Biosciences Inc (ANIX.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences ( ANIX – Research Report ), with a price target of $12.00. The company’s shares closed ...
SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...
Analyst's Opinion · Consensus Rating. Anixa Biosciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' consensus ...
The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial. SAN JOSE, Calif. , May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction ... 6 months ago - PRNewsWire.SAN JOSE, Calif., Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused...In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences ( ANIX – Research Report ), with a price target of $12.00. The company’s shares closed ...Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of …SAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...Apr 18, 2023 · Anixa Biosciences (ANIX) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, with a price target of $12.00 . The company’s shares closed last ... Oct 23, 2023. Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardView the latest Anixa Biosciences Inc. (ANIX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology ...Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | BOERSE MUENCHEN: CY71 | BOERSE MUENCHENAnixa Biosciences Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for ANIX stock stock is $10.5, which predicts an increase of 258.36%. The lowest target is $9.00 and the highest is $12. On average, analysts rate ANIX stock stock as a strong buy.Anixa Biosciences (Nasdaq:ANIX) - Stock Price, News & Analysis - Simply Wall St Stocks / Pharmaceuticals & Biotech Anixa Biosciences NasdaqCM:ANIX …Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its …Instagram:https://instagram. 5 best lithium stocksbest stock options brokersferrari racelqd ticker Oct 27, 2023 · The following insiders have purchased ANIX shares in the last 24 months: Amit Kumar ($69,540.00), Lewis H Titterton Jr ($155,021.44), and Michael Catelani ($26,367.77). How much insider buying is happening at Anixa Biosciences? Insiders have purchased a total of 71,253 ANIX shares in the last 24 months for a total of $250,929.21 bought. bddy stockpazoo About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a … otckx Anixa Biosciences Inc. (NASDAQ: ANIX) stock closed at 3.22 per share at the end of the most recent trading day (a 0.63 % change compared to the prior day closing price) with a volume of 22.49K shares and market capitalization of 100.05M.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical …Looking more specifically, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry, which includes 554 individual stocks and currently sits at #78 in the Zacks Industry Rank.